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Abstract
While it is known that those who are living their last years are frequent users of social and health services, research about 
medicines at the end of life is scarce. We examined whether the proportions of purchasers and the types of prescription 
medicines purchased during a 2-year period differed between community-dwelling old people who died (decedents) in 
2002, 2006 or 2011 and old people who lived at least 2 years longer (survivors) in Finland. We also examined how those 
differences changed over time. The study population was identified from nationwide registers and consisted of 174,097 
community-dwelling people who were 70 years of age or older. Of these, 81,893 were decedents and 92,204 survivors. Data 
on purchases of medicines were gathered from the Finnish prescription database. Along with descriptive analyses, binary 
logistic regression analysis was used to find the association between decedent status and the purchase of medicines in general 
and different categories of medicines in particular. Almost all community-dwelling decedents and survivors purchased medi-
cines at least once during the 2-year period. Over time, the proportion of purchasers increased in both groups but especially 
among survivors, thereby reducing the differences between the groups. However, the probability of purchasing medicines 
in general and different categories of medicine in particular remained significantly higher for decedents than for survivors 
after adjustments. This study shows that purchases of medication are concentrated at the end of life, as is the use of social 
and health services. However, the differences between decedents and survivors diminish over time.
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Introduction
The use of medicines among old people is very common and 
rapidly increasing (Barat et al. 2000; Crockett 2005; Fimea 
2016). Medication has become commoner as the prevalence 
of diseases in old age has increased (Crimmins and Beltrán-
Sánchez 2011), and diseases are more often treated with 
medicines (Giron et al. 1999).
The use of medicines differs between the oldest old and 
the youngest old (Gislason et al. 2005; Wastesson et al. 
2012), between old men and old women (Bell et al. 2009; 
Gislason et al. 2005; Pokela et al. 2010) and between those 
living in different types of housing (Johnell and Fastbom 
2012; Jyrkkä et al. 2006; Linjakumpu et al. 2002). Previous 
studies have also reported that old people at the end of life 
are frequent users of medicines (McNeil et al. 2016; Morin 
et al. 2017). While it is well known that those who are living 
their last years and months are frequent users of social and 
health services comparing to those who lived longer (Forma 
2011; Lunney et al. 2007; Murphy and Martikainen 2013; 
Pot et al. 2009), the evidence on differences in medication 
is still scarce (Forma et al. 2007; Menec et al. 2007; Hoover 
et al. 2002).
Due to multimorbidity, old people at the end of life are 
particularly at risk of polypharmacy and related adverse 
effects (Cruz-Jentoft et  al. 2012; Paque et  al. 2019a; 
Holmes et  al. 2006). There is no consistent definition 
for polypharmacy, and especially it is not clear when it 
is appropriate and when inappropriate (Mortazavi et al. 
2016). For example, in outpatient settings, the number 
of four medicines has often been used as a dividing line 
Responsible editor: Dorly J. H. Deeg.
 * Jutta Pulkki 
 jutta.pulkki@tuni.fi
1 Faculty of Social Sciences, Tampere University, Tampere, 
Finland
 European Journal of Ageing
1 3
for polypharmacy (Rollason and Vogt 2003), referring to 
multiple use of medicines but not necessary on inappropri-
ate medication. It has been suggested that the otherwise 
appropriate medication of frail old people, especially those 
with limited life expectancy, should be reconsidered and 
unnecessary medicines are deprescribed (Holmes et al. 
2006; Paque et al. 2019a). However, this is not often the 
case in practice, and numerous studies have demonstrated 
the frequent use of unnecessary and inappropriate medica-
tion among old people near death (Maddison et al. 2011; 
Curtin et al. 2018; Paque et al. 2019b).
Polypharmacy, especially the inappropriate medicine 
usage, is not just a disadvantage at the individual level, but 
increases also the public costs of medicines in countries with 
inclusive public welfare systems. In Finland, for example, 
the health insurance scheme covers a high proportion of 
medicine expenditures for all permanent residents. Reim-
bursements are paid for almost all medicines prescribed 
by medical doctors and purchased by community-dwelling 
people, e.g. those who live at home or in service houses. 
Ninety-five per cent of those aged 65 or older obtained reim-
bursements in 2015, and reimbursements were commoner 
among the oldest old than the younger old (Fimea 2016).
Among old people in Finland, the living in institutions 
such as nursing homes has dramatically decreased and the 
living in community settings, especially in service houses 
with 24-h care, has steadily increased, since the beginning 
of the twenty-first century (National Institute for Health and 
Welfare 2017). Institutional care and community care facili-
ties serve similar care needs, but their financing differs. First, 
in institutions, all costs including medicines are included in 
the monthly care fee, and purchases of medicines are not 
shown on national registers. In service houses, on the other 
hand, residents are considered to be home-dwelling and they 
need to pay separately for everything themselves, includ-
ing rent, care services, food, medicines, etc. This shift from 
all-inclusive institutional care to community care where old 
people purchase medicines themselves has resulted in grow-
ing proportions of purchasers and increased reimbursements 
for prescribed medicines in Finland (Aaltonen et al. 2016; 
Blomgren and Einiö 2015).
This study focused on the proportion of purchasers and 
the types of prescribed medicine purchased by community-
dwelling old people at the end of life and by those who 
lived at least 2 years longer. It also focused on how those 
purchases changed over time. The results reveal increased 
trends in old people’s purchases of medicines in an era when 
community care arrangements have become considerably 
commoner in Finland. Purchases of medicine were studied 
for the 2 years prior to death among those who died (dece-
dents) at the age of 70 or older in the years 2002, 2006 and 
2011, and for the same period among old people who lived 
for at least 2 years after 2002, 2006 and 2011 (survivors). 
The detailed research questions were as follows: (1) How 
did the proportions of purchasers and the types of medicine 
purchased differ between decedents and survivors? (2) How 
did these differences change between the years 2002, 2006 
and 2011?
Materials and methods
Study population
This study is part of a larger project called ‘New dynamic 
of longevity and the changing needs for services’ (COC-
TEL). The original COCTEL data include all those 
who died in Finland at the age of 70 years or older in 
2002–2013. Decedents were identified from the nation-
wide Causes of Death Register (maintained by Statistics 
Finland). For almost every decedent, a surviving counter-
part, i.e. a person who lived at least 2 years longer, was 
identified from the Finnish Population Information System 
(maintained by Statistics Finland), using 40% random sam-
ples of persons born in the same year as the decedent. In 
the original COCTEL data, the survivors are individually 
matched with corresponding decedents according to age, 
gender and municipality of residence. For more details on 
the COCTEL study design, see Forma (2011).
In this study, the groups of decedents for the years 
2002, 2006 and 2011 were compared with the groups of 
survivors for each year. In the original COCTEL data, the 
number of decedents and survivors was 29,337 in 2002, 
32,140 in 2006 and 34,036 in 2011. Community-dwell-
ing people were identified among these and selected for 
this study, since purchases of medicines by people living 
in institutions are not registered. The identification was 
made using data from the Care Register for Healthcare 
and the Care Register for Social Welfare (both maintained 
by the National Institute for Health and Welfare), which 
are linked to each person in the COCTEL data. First, as 
the register data do not explicitly count days at home, old 
people who had no registered days in any social or health-
care institution were considered to be living at home. Sec-
ond, people living in service housing with 24-h care were 
considered to be community-dwelling, as they buy their 
own medicines. All those who lived for at least 90 of the 
730 days at home or in service housing during the 2-year 
study period were included in the study population. It was 
probable that people would have purchased any necessary 
medicines within those 90 days, as many medicine pre-
scriptions are for three months.
Appendix Table 5 shows the proportions of community-
dwelling decedents and survivors in the original COCTEL 
data set. Because of the inclusion of community dwellers 
only, the matched pairs were no longer accurate, and the 
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comparisons were made at group level instead of indi-
vidual level.
Permission to use individualized data was granted to 
COCTEL by the registers’ administrators, and the study 
plans were approved by the Pirkanmaa Hospital District 
Ethics Committee.
Data on purchases of medicines
Purchases of prescribed medicines are recorded on 
national registers in Finland as well as in other Nor-
dic countries, and these registers are often used as data 
sources in medicine usage studies (Bell et al. 2009; Gis-
lason et al. 2005; Johnell and Fastbom 2012; Wastesson 
et al. 2012; Morin et al. 2017). In this study, data regard-
ing the date and type [using WHOCC (2013) five-level 
Anatomical Therapeutic Chemical (ATC) codes] of each 
purchase of medicine were collected from the National 
Prescription Register maintained by the Social Insurance 
Institution. Information on each person’s purchases of pre-
scribed medicines was collected for a 2-year period: for 
decedents, 2 years (730 days) prior to death; for survivors, 
for the same calendar days as their decedent counterpart. 
Data from the National Prescription Register and other 
registers were linked using the unique individual identifi-
cation code possessed by every Finnish resident.
Each purchase of medicine was categorized as belong-
ing to one of the 14 main ATC categories. Dichotomous 
variable was created to describe whether a person had 
purchased any medicines at least once during the 2-year 
period (0 = no purchases, 1 = at least one purchase), and 
whether a person had purchased separate medicines in 
each of the 14 main categories. Dummy variables indicat-
ing purchases in these main categories were calculated 
together to reveal how many ATC categories of decedents 
and survivors had bought medicines within the 2 years. 
This variable could have values from 0 to 14. A dichoto-
mous outcome was created from this variable by dividing 
it to those who purchased medicines from less than four, 
or at least four ATC categories to indicate polypharmacy. 
This means that people have purchased at least four differ-
ent medicines but maybe even more, if they have bought 
more than one item of drugs from one ATC category.
Data on days in a community‑dwelling setting
Each person’s days spent in community-dwelling settings, 
i.e. at home or in service housing with 24-hour care, were 
calculated on the basis of admission and discharge dates 
recorded in the Care Register for Healthcare and the Care 
Register for Social Welfare. The continuous variable ‘the 
number of days in community settings’ was created, to iden-
tify community dwellers and adjust the length of stay in the 
community, where medicine purchases could take place. The 
adjustment was needed because it is known that decedents 
have more days in institutions where medication is included 
in the care, and because the days in community-dwelling set-
tings increased significantly within the study period, thereby 
also increasing the opportunities to buy medicines.
Analysis
To analyse the differences between decedents and survi-
vors in the different years, the proportions of purchasers 
of medicines were analysed, both in total and separately 
for each ATC category, by using cross-tabulations, chi-
square tests and rate ratios. An independent sample t test 
was used to compare the differences in means of medi-
cine purchases in several ATC categories. Analyses were 
conducted separately for the years 2002, 2006 and 2011, 
for men and women, and for different age groups (70–79, 
80–89 and at least 90 years).
Binary logistic regression models were used to com-
pare the likelihood of the purchase of medicines in total, 
purchases in at least four ATC categories, and purchases 
in the commonest ATC categories, among decedents and 
survivors. The models were run stepwise: in crude models, 
status (decedent versus survivor) was used as an independ-
ent variable; in model 1, status, age, gender, year (of death), 
the number of days in community-dwelling settings and the 
interaction term (status*year) were used. The interaction 
term was used to examine whether the effect of decedent sta-
tus changed over time. If the p value was less than 0.001, it 
was concluded that the difference was significant. The analy-
ses were performed with SPSS (v.22) statistical software.
Results
Description
The study population comprised in total 174,097 commu-
nity-dwelling old people, and the proportion of community 
dwellers increased between the study periods. The mean age 
of the study population increased too, especially the pro-
portion of people aged 90 and older (Table 1). The mean 
number of days lived in the community increased steadily 
between the study periods among decedents, whereas sur-
vivors showed only minor changes.
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Purchasers of medicines
Altogether, 93–98% of community-dwelling old people 
purchased prescribed medicines within the 2-year period, 
with an increase from 2002 to 2011. While decedents 
bought medicines more frequently than survivors in 2002, 
the difference diminished in 2006, and in 2011 survivors 
purchased medicines slightly more frequently than dece-
dents. This trend was shown in different age groups. Even 
though the differences in total purchases between dece-
dents and survivors were statistically significant, absolute 
differences were very small (rate ratios (RR) = 1.03, 1.02 
and 1.00, separately) (Table 2). 
Also in logistic regression model 1, the interaction 
term (status*year) indicates that the difference between 
decedents’ and survivors’ total purchases of medicines 
fell from 2002 to 2011 [odds ratio (OR) = 0.48)]. How-
ever, decedents still bought medicines slightly more 
often after adjustment for age, gender and the number of 
days in community settings (in 2002 OR = 2.10; in 2011 
OR = 2.10*0.48 = 1.01) (Table 3).
Purchases in several ATC categories
Medicines from four or larger number of ATC categories 
were purchased more often during the latest study period 
than during earlier years, by both decedents and survivors. 
Figure 1 shows that the decedents bought medicines from 
five and more ATC categories more often than survivors 
within the 2 years preceding the years 2002 and 2006, and 
six and more ATC categories in year 2011. The shift over 
time was seen more clearly among those who lived at least 
2 years longer, reducing the difference between decedents 
and survivors (Fig. 1, Table 2).
The adjusted results showed also that the difference 
between the status groups in medicines purchased from 
at least four ATC categories diminished comparing 
the year 2011  to 2002 (status*year OR = 0.74). How-
ever, in 2011 decedents still bought medicines from at 
least four ATC categories more often than did survivors 
(OR = 2.47*0.74 = 1.83) (Table 3).
Purchases by ATC category
Decedents purchased medicines in most of the ATC cat-
egories significantly more commonly than did survivors, 
but the differences diminished over time (RRs, Table 2). 
Both decedents and survivors most commonly purchased 
medicines belonging to the ‘cardiovascular’ (C) category. 
In addition, purchases in the categories ‘central nervous 
system’ (N, including for example medication for Alzhei-
mer’s disease), ‘alimentary tract’ (A, including drugs used in 
diabetes), ‘anti-infectives’ (J, including drugs used in infec-
tions) and ‘musculoskeletal system’ (M, including muscle 
relaxants and painkillers) were common in both groups. The 
frequency of buying medicines increased from 2002 to 2011 
in all of these categories except M (Table 2).
The differences between decedents and survivors in 
purchases of medicines in the five most common catego-
ries (A, C, J, M and N) diminished from 2002 to 2011 
after adjustments for age, gender and the number of days 
Table 1  Description of the study population
2002 2006 2011
Decedents Survivors Total Decedents Survivors Total Decedents Survivors Total
n = 24,797 n = 28,285 n = 53,082 n = 27,187 n = 30,675 n = 57,862 n = 29,909 n = 33,244 n = 63,153
Men (%) 45.5 43.2 44.3 46.4 44.2 45.3 46.2 44.8 45.4
Mean age 80.3 80.7 80.5 82.0 82.3 82.1 82.7 83.0 82.8
Age groups 
(%)
 70–79 46.5 43.9 45.1 37.1 35.2 36.1 32.3 30.8 31.5
 80–89 47.1 48.8 48.0 48.5 49.4 49.0 51.5 51.7 51.6
 At least 90 6.4 7.3 6.9 14.3 15.4 14.9 16.2 17.5 16.9
Days in 
commu-
nity-dwell-
ing settings
 Mean (SD) 615.5 
(148.1)
710.9 (68.4) 666.4 
(122.5)
619.5 
(145.4)
707.0 (77.1) 665.9 
(122.5)
632.6 
(132.9)
711.9 (65.4) 674.4 (110.4)
 Median 675.0 730.0 720.0 678.0 729.0 718.0 684.0 730.0 721.0
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in community (ORs for interaction term status*year > 1, 
separately). However, in 2011 decedents still bought 
medicines more often than survivors in all categories (for 
A OR = 2.36*0.84 = 1.98; C OR = 1.37; J OR = 1.56; N 
OR = 1.91) other than M (OR = 1.35*0.71 = 0.96) (Table 4).
Discussion
Almost all community-dwelling old people purchased med-
icines within the 2-year study periods. The proportion of 
purchasers of medicines increased among both decedents 
and survivors from 2002 to 2011, which is in line with the 
general trend of increasing prescription numbers and medi-
cine usage among old people in Finland (Jyrkkä et al. 2006; 
Linjakumpu et al. 2002). During the study period, the shift 
from institutions to community care has been dramatic in 
Finland (National Institute for Health and Welfare 2017) and 
is shown also in increased purchases of prescribed medicines 
(see Blomgren and Einiö 2015). Our results reflect this shift 
too.
Our results show that not only those community-dwelling 
old people who lived their last years (McNeil et al. 2016; 
Morin et al. 2017) but also those who were surviving longer 
become more frequent purchasers of medicines. The differ-
ences in proportions of purchasers in total and in different 
ATC groups reduced between decedents and survivors dur-
ing the study period. Based on our analysis, we cannot give 
a full explanation of why the differences between the groups 
diminished. We can say, though, that as age was controlled 
for in our analysis, the fact that people in our study popula-
tion—especially survivors—were older year by year does 
not explain the decrease in the differences. The proportion 
of the oldest old was higher among survivors than among 
decedents, because the oldest old near death more frequently 
live in institutions (see Appendix Table 5). The results might 
have changed, although probably not dramatically, if our 
data had included purchases made by the most ill oldest old 
who were living their last years in institutions.
While decedents bought medicines more commonly than 
survivors in almost all ATC categories, survivors were more 
likely to purchase medicines in ATC categories for genito-
urinary systems and sensory organs, i.e. for less severe 
illnesses. That is, at least some of the differences may be 
attributable to the different diseases and the severity of 
these. The shift in long-term care arrangements in Finland 
has most probably changed health conditions and the need 
for medicines of old people living in the community. Thus, 
people living in the community in 2011 compared with 2002 
were not just older (Appendix Table 5) but probably also 
had different health status, which may explain the changes 
in purchases of medicines in both groups. However, we can 
only speculate this as neither the health status nor the indica-
tions for the medications were available for the community 
dwellers in our data.
Table 3  Purchases of medicines among decedents and survivors—in 
total, and from four or more ACT categories; odd ratios from logistic 
regression models
a Crude = only independent variable was decedent status
b Model 1 = crude + adjusted for age, gender, year, days at community-
dwelling setting, and interaction between decedent status and year
Sig < 0.001—bolded
Purchases in total ≥ 4 ATC 
Crudea Model  1b Crudea Model  1b
Status
(surv = ref)
1.40 2.10 2.22 2.46
Year
(2002 = ref)
2006 1.19 1.06
2011 3.45 2.27
Status*year
(2002 = ref)
2006 0.97 1.01
2011 0.48 0.74
Fig. 1  Total number of ATC 
categories (min 0, max 14) from 
which survivors and decedents 
bought medicines within 2 years 
preceding the years 2002, 2006 
and 2011
0
1000
2000
3000
4000
5000
6000
0 1 2 3 4 5 6 7 8 9 10111213 0 1 2 3 4 5 6 7 8 9 10111213 0 1 2 3 4 5 6 7 8 9 10111213
2002 2006 2011
N of purchasers Survivor Decedent
European Journal of Ageing 
1 3
The increased use of medicines may also reflect chang-
ing trends in healthcare practices. In our study, however, the 
study period was relatively short, while most of the changes 
in diagnostic or more active care have occurred over a longer 
time span (Crimmins and Beltrán-Sánchez 2011). Instead, 
the changes in Finnish reimbursement policies are known to 
have influenced medication purchases, as well as prescrip-
tion practices at short notice. For example, purchases of 
medicines for Alzheimer’s disease (ATC codes in the N06D 
category) are increasing, partly because these medicines are 
increasingly reimbursed out of national health insurance and 
their prices declined soon after their approval by the subsi-
dies programme (Aaltonen et al. 2016). In addition, some 
medicines—for example, those in the musculoskeletal cat-
egory—can increasingly be bought over the counter without 
a prescription and are therefore not shown in national reg-
isters. These kinds of change in reimbursement and other 
criteria were made to numerous medicines in Finland during 
the study period, and they may explain some of the temporal 
changes in this study.
Medicines in the cardiovascular, central nervous system, 
alimentary tract and anti-infectives categories were those 
most commonly purchased by community-dwelling old 
people in their last years of life. Medicines in these catego-
ries, except anti-infectives, have been found to be the most 
commonly used among old people in several studies (Barat 
et al. 2000; Giron et al. 1999; Linjakumpu et al. 2002). The 
proportion of those buying medicines for cardiovascular dis-
eases at the end of life was relatively high compared with 
other studies (Barat et al. 2000; Giron et al. 1999; Mizokami 
et al. 2012), but was similar to numbers reported in previous 
Finnish studies (Jyrkkä et al. 2006; Linjakumpu et al. 2002). 
This might be a result of differences in the data rather than 
in clinical practices between countries.
It has been found that the inappropriate use of medicines 
is commoner in community settings, where medication is 
not carefully supervised than it is in nursing homes staffed 
by healthcare professionals (Elliot 2006; Lane et al. 2004). 
Our purpose was not to go into the details of whether medi-
cation is inappropriate, but to show the trends of polyphar-
macy, which may also indicate the inappropriate medication. 
Our results show that purchases of medicines from several 
ATC categories, i.e. polypharmacy, increased, a trend that 
has also been shown in previous studies (Hajjar et al. 2007; 
Haider et al. 2007; Hovstadius et al. 2010). Our results high-
light the need to monitor and reconsider the medication of 
the increasing number of community-dwelling old people, 
in order to reduce the risk of adverse effects related to inap-
propriate medication, particularly when life expectancy is 
Table 4  Purchases of medicines among decedents and survivors by the most common ACT categories, odds ratios from logistic regression mod-
els
a A = alimentary tract/metabolism
b C = cardiovascular
c J = anti-infectives for systemic use
d M = musculoskeletal system
e N = central nervous system
f Crude = only independent variable was decedent status
g Model 1 = crude + adjusted for age, gender, year, days at community-dwelling setting and interaction between decedent status and year
Sig < 0.001—bolded, Sig < 0.05—italicized
Aa Cb Jc Md Ne
Crudef Model  1g Crudef Model  1g Crudef Model  1g Crudef Model  1g Crudef Model  1g
Status
(surv = ref)
1.26 2.36 1.53 1.99 1.79 1.88 1.10 1.35 2.36 2.33
Year
(2002 = ref)
2006 1.18 1.34 0.83 0.90 1.21
2011 2.15 2.18 1.51 0.89 3.20
Status* year
(2002 = ref)
2006 1.00 0.86 1.12 0.92 0.92
2011 0.84 0.69 0.83 0.71 0.82
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limited (Lane et al. 2004; Holmes et al. 2006; Maddison 
et al. 2011).
A few limitations need to be addressed concerning the 
data. It is likely that people in the survivors group in earlier 
years may be survivors or decedents in later years. As our 
research data did not allow to take this possible overlapping 
into account, this may potentially threaten the internal valid-
ity of the study. Overlapping may decrease the standard error 
and thus increase statistically significant findings. However, 
we surmise that the overlapping is minor as the survivors 
were identified from the 40% random sample, they may have 
died in a different year than studied, or they may not live in 
the community anymore. Also, in the case of overlapping, 
people’s situations may have altered so rapidly, as at old age 
they often do, that the effects on the results are indifferent.
The Finnish Prescription Register includes information 
on all medicine purchases reimbursed by the health insur-
ance scheme, but only for residents living in non-institu-
tional settings. Therefore, our findings only apply to those 
who were living at home or in service housing. Addition-
ally, the Prescription Register includes only prescription 
medicines, not over-the-counter medicine purchases. For 
purchases of prescribed medicines, Finland’s administrative 
registers have been found to be reliable and comprehensive 
(Gissler and Haukka 2004). Therefore, in our understand-
ing, our study reliably describes the trends in purchases of 
medicines among community-dwelling old people. How-
ever, such purchases do not reveal whether the medicines 
are actually used; to study this, methods other than registers 
are needed (Barat et al. 2000; Linjakumpu et al. 2002; Miz-
okami et al. 2012).
Conclusions
This study shows the growing proportion of medication 
purchasers among community-dwelling old people, along 
with increasing longevity and the trend of living in the 
community. Community-dwelling old people in their last 
2 years of life purchased medicines more frequently than 
those who lived at least 2 years longer, but the differences 
decreased over time. The reasons for the diminished dif-
ferences and whether the differences between these two 
groups have changed further in more recent years are yet to 
be investigated.
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See Table 5.
Table 5  Proportions of 
community-dwelling people of 
the original COCTEL dataset—
decedents and survivors in years 
2002, 2006 and 2011, by gender 
and age (n = for total COCTEL 
dataset)
2002 2006 2011
Decedents Survivors Decedents Survivors Decedents Survivors
COCTEL dataset n = 29,337 n = 29,337 n = 32,140 n = 32,140 n = 34,036 n = 34,036
% of all 84.5 96.4 84.6 95.4 87.9 97.7
Gender (%)
Men 90.5 98.2 90.9 97.7 91.8 98.8
Women 80.1 95.1 79.8 93.7 84.7 96.8
Age group (%)
70–79 91.6 98.8 92.5 98.9 93.7 99.4
80–89 81.1 95.7 83.3 95.7 87.6 97.8
At least 90 67.8 87.9 72.4 87.7 78.9 94.4
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